舒利迭联合无创通气抢救老年慢阻肺呼吸衰竭患者临床观察  

Effect of Seretide combined with noninvasive positive pressure ventilation on treating patients with type Ⅱ respiratory failure due to chronic obstructive pulmonary disease

作　　者：陈振平[1] 刘学芬[1] 黄晓霞[1] 肖卫[1] 

机构地区：[1]湖北省荆州市第一人民医院呼吸内科,湖北荆州434000

出　　处：《海南医学院学报》2012年第3期317-319,共3页Journal of Hainan Medical University

基　　金：中国高校医学期刊临床专项资金项目(11221060)~~

摘　　要：目的:探讨舒利迭联合无创通气在治疗老年慢性阻塞性肺疾病(COPD)呼吸衰竭的临床疗效。方法:将120例COPD伴有Ⅱ型呼吸衰竭的患者随机分为对照组与观察组,每组60例,两组患者均给予常规治疗。对照组给予双水平气道正压通气(BiPAP)治疗,观察组患者给予舒利迭联合BiPAP治疗,比较两组患者治疗前后血气分析、肺功能变化。结果:治疗后48h观察组PaO2、PaCO2及PH值显著优于对照组(P<0.05);观察组肺功能FEVl、FEV1/FVC、FEV1占预计值百分比显著高于对照组,差异具有统计学意义(P<0.05)。结论:舒利迭联合BiPAP治疗COPD伴有Ⅱ型呼吸衰竭可快速减轻患者临床症状,改善生化指标及肺功能,疗效优于单用BiPAP治疗。To explore the clinical effect of Seretide combined with noninvasive positive pressure ventilation in treating patients with type 1I respiratory failure caused by chronic obstructive pulmonary disease （COPD）. Methods. A total of 120 cases with COPD were randomly divided into control group and experimental group with 60 patients each group. Patients in both two groups received routine treatment. Patients in control group were given BiPAP treatment, and experimental group received BiPAP combined with Seretide treatment. Blood gas analysis and lung function were compared between two groups. Results：PaO2, PaCO2 and PH 48 hour after treatment in experimental group were superior to control group （P〈0.05）, and FEV1, FEV1/FVC, FEVIM were significantly higher in experimental group （P%0.05）. Conclusions：BiPAP combined with Seretide treatment can alleviate clinical symptoms quickly and improve blood gas analysis indexes and lung function. The effect is superior to single BiPAP treatment.

关 键 词：慢性阻塞性肺疾病 无创通气 舒利迭 

分 类 号：R56[医药卫生—呼吸系统]